Cardiac Safety of Dual Anti‐HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2‐Positive Breast Cancer

BACKGROUND. Trastuzumab and pertuzumab are approved for the neoadjuvant treatment of human epidermal growth receptor 2 (HER2)‐positive breast cancer, but cardiac safety data is limited. We report the cardiac safety of dose‐dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel, trastuzum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Yu, Anthony F., Singh, Jasmeet C., Wang, Rui, Liu, Jennifer E., Eaton, Anne, Oeffinger, Kevin C., Steingart, Richard M., Hudis, Clifford A., Dang, Chau T.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5469581/
https://ncbi.nlm.nih.gov/pubmed/28341761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0406
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados